Ulf Landmesser Articles
VIDEO: Do FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?
read more »Posted on 16 March 2018 |
Posted by Ulf Landmesser | Posted in Videos,
67th Annual Scientific Sessions of the American College of Cardiology 2018
ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors
This Task Force from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) has considered new evidence from cardiovascular outcomes studies with evolocumab (FOURIER) and bococizumab (now terminated), new analyses and genetic studies.t Taking account of the cost of these agents, the Task…
read more »
How do we identify very high risk patients for PCSK9 inhibition? Part Two
Reports from the 7th Expert Meeting of PCSK9 Forum The role of imaging: Ulf Landmesser, Charité Universitätsmedizin Berlin, Germany
read more »Posted on 18 October 2017 |
Posted by Ulf Landmesser | Posted in Webcasts,
7th Closed Scientific Expert Meeting of the Editorial Board
Prof Ulf Landmesser: How can we ensure the best value from PCSK9 inhibitor therapy?
read more »Posted on 20 March 2017 |
Posted by Ulf Landmesser | Posted in Videos,
66th Annual Scientific Sessions of the American College of Cardiology 2017
Prof Ulf Landmesser: How will FOURIER impact practice?
read more »Posted on 20 March 2017 |
Posted by Ulf Landmesser | Posted in Videos,
66th Annual Scientific Sessions of the American College of Cardiology 2017
The year in cardiology 2015: prevention
PCSK9 Forum Editors, Profs John Chapman, Ulf Landmesser and co-authors discuss the highlights of 2015 in The European Heart Journal.
read more »
